ANTHIM
PeakmAbobiltoxaximab
BLAINJECTIONINJECTABLE
Approved
Mar 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ANTHIM (obiltoxaximab) is anthrax protective antigen-directed antibody interactions [moa]. Approved for inhalational anthrax due to b, treat meningitis. First approved in 2016.
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANTHIM (obiltoxaximab) is a monoclonal antibody that binds to anthrax protective antigen, neutralizing the toxin's effects. It is indicated for inhalational anthrax and treatment of anthrax-associated meningitis. The drug works by blocking the pathogenic mechanism of anthrax toxin, preventing cellular damage.
Peak
As a niche biodefense product in peak lifecycle, the brand team is likely focused on maintaining market access and supporting healthcare preparedness programs rather than expansion.
Mechanism of Action
Anthrax Protective Antigen-directed Antibody Interactions
Pharmacologic Class:
Anthrax Protective Antigen-directed Antibody
Indications (2)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.